{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Motzer RJ"],"funding":["NCI NIH HHS"],"pagination":["1160-1170"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10191771"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(9)"],"pubmed_abstract":["The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for genetic testing, surveillance, and/or treatment options for patients who are suspected or confirmed to have one of these syndromes."],"journal":["Journal of the National Comprehensive Cancer Network : JNCCN"],"pubmed_title":["NCCN Guidelines Insights: Kidney Cancer, Version 1.2021."],"pmcid":["PMC10191771"],"funding_grant_id":["K12 CA090625"],"pubmed_authors":["Agarwal N","Kyriakopoulos C","Pierorazio PM","Jonasch E","Alva A","Manley B","Mortazavi A","Ramalingam S","Beckermann K","Smith ZL","Madoff DC","Michaelson MD","Dwyer MA","Ponsky L","Derweesh IH","Costello BA","Haas N","George S","Shuch B","Nandagopal L","Sosman J","Choueiri TK","Lam ET","McCreery B","Motter AD","Boyle S","Desai A","Lewis B","Plimack ER","Carlo MI","Motzer RJ","Gore JL","Hancock SL","Somer B","Lau C"],"additional_accession":[]},"is_claimable":false,"name":"NCCN Guidelines Insights: Kidney Cancer, Version 1.2021.","description":"The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on recent updates to the guidelines, including changes to certain systemic therapy recommendations for patients with relapsed or stage IV RCC. They also discuss the addition of a new section to the guidelines that identifies and describes the most common hereditary RCC syndromes and provides recommendations for genetic testing, surveillance, and/or treatment options for patients who are suspected or confirmed to have one of these syndromes.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2026-04-08T13:17:29.322Z","creation":"2025-02-19T04:43:59.08Z"},"accession":"S-EPMC10191771","cross_references":{"pubmed":["32886895"],"doi":["10.6004/jnccn.2020.0043"]}}